Here are five things to know:
1. Merck attributed the profit to a big jump in U.S. medicine sales, particularly for its blockbuster cancer drug Keytruda. Keytruda boosts a patient’s immune system to fight cancer.
2. The loss in the third quarter of 2017 was a result of several one-time expenses, including a cyberattack in June of that year that shut down production.
3. Overall, Merck reported $10.8 billion in global sales in the third quarter of 2018, up 5 percent from the same period one year prior.
4. During the earnings call, the company said it was initiating a $10 billion share buyback program.
5. “We built on our strong momentum during the quarter and believe that Merck is well-positioned to continue creating sustainable value for shareholders and patients,” said Kenneth C. Frazier, Merck chairman and CEO.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
